A prospective observational case-report study now shows that thalidomide can be a well-tolerated, efficacious treatment for complications such as pain, bleeding and ulceration from extracranial arteriovenous malformation.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Liu, A. S. et al. Plast. Reconstr. Surg. 125, 1185–1194 (2010).
McDonald, J. & Stevenson, D.A. GeneReviews (eds. Adam, M.P. et al.) (University of Washington, 1993).
Amyere, M. et al. Circulation 136, 1037–1048 (2017).
Revencu, N. et al. J. Med. Genet. 57, 48–52 (2020).
Scherschinski, L. et al. World. Neurosurg. 159, 327–337 (2022).
Smits, P. J. et al. Biochem. Biophys. Res. Commun. 529, 450–454 (2020).
Boon, L. M. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-022-00080-2 (2022).
Invernizzi, R. et al. Lancet Haematol. 2, e465–e473 (2015).
Komorowski, J. et al. Life Sci. 78, 2558–2563 (2006).
Lekwuttikarn, R. et al. JAMA Dermatol. 155, 256–257 (2019).
The authors declare no competing interests.
About this article
Cite this article
Teng, J.M.C., Siegel, D.H. A new tale of thalidomide repurposing. Nat Cardiovasc Res 1, 535–536 (2022). https://doi.org/10.1038/s44161-022-00087-9